Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1886-1896

  Prosperi, Mattia C F ^a,b,c   Mackie, Nicola ^d   di Giambenedetto, Simona ^a   Zazzi, Maurizio ^e   Camacho, Ricardo ^f   Fanti, Iuri ^a   Torti, Carlo ^g   Sönnerborg, Anders ^h   Kaiser, Rolf ⁱ   Codoñer, Francisco M ^j   van laethem, Kristel ^k   Bansi, Loveleen ^l   van de Vijver, David A M C ^m   Geretti, Anna Maria ^l   de luca, Andrea ^a,n  

^a CATHOLIC UNIVERSITY   (Italy)

^b Dimensione Ricerca   (Italy)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^e UNIVERSITY OF SIENA   (Italy)

^f Centro Hospitalar de Lisboa Central   (Portugal)

^g UNIVERSITY OF BRESCIA   (Italy)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j IrsiCaixa Foundation   (Spain)

^k REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^l ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^m ERASMUS MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY HOSPITAL OF SIENA   (Italy)

more..

Author keywords

Genotypic testing; HIV; Viral load

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE MUTATION; EUROPE; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MEDICAL HISTORY; MULTICENTER STUDY; MUTATIONAL ANALYSIS; PROBABILITY; RNA ANALYSIS; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; EUROPE; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; RNA, VIRAL; VIRAL LOAD; VIRAL PROTEINS;

EID: 79960443775     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr171     Document Type: Article

References (28)

1. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. January 10, 2011, pp. 1-166. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGl.pdf (5 January 2011, date last accessed).
2. Ceccherini-Silberstein F, Cento V, Calvez V et al. The use of human immunodeficiency virus resistance tests in clinical practice. Clin Microbiol Infect 2010; 16: 1511-7.
3. Gale HB, Kan VL, Shinol RC. Performance of the TruGene human immunodeficiency virus type 1 genotyping kit and OpenGene DNA sequencing system on clinical samples diluted to approximately 100 copies per milliliter. Clin Vaccine Immunol 2006; 13: 235-8.
4. Stelzl E, Troppan KT, Winkler M et al. Optimized protocol for detection of HIV-1 drug mutations in patients with low viral load. J Virol Methods 2010; 168: 152-4.
5. Yang Z, Morrison R, Oates C et al. HIV-1 genotypic resistance testing on low viral load specimens using the Abbott ViroSeq HIV-1 genotyping system. Labmedicine 2008; 39: 671-3.
6. Mitsuya Y, Winters MA, Fessel WJ et al. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL. J Acquir Immune Defic Syndr 2006; 43: 56-9.
7. Mackie N, Dustan S, McClure MO et al. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Methods 2004; 119: 73-81.
8. Cane PA, Kaye S, Smit E et al. Genotypic antiretroviral drug resistance at low viral loads in the UK. HIV Med 2008; 9: 673-6.
9. Mackie NE, Phillips AN, Kaye S et al. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis 2010; 201: 1303-7.
10. Waters L, Mandalia S, Asboe D. Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/mL. AIDS 2006; 20: 778-9.
11. EuResist Foundation GEIE. www.euresist.org/ (5 January 2011, date last accessed).
12. Virolab EU Project. http://www.virolab.org/ (5 January 2011, date last accessed).
13. UK Collaborative Group on HIV Drug Resistance. http://www.hivrdb.org.uk/ (5 January 2011, date last accessed).
14. IrsiCaixa Foundation. http://www.irsicaixa.org/ (5 January 2011, date last accessed).
15. Di Giambenedetto S, Dunn D, Zazzi M et al. Calendar trends in antiretroviral drug resistance in treatment-experienced patients in Europe. HIV Med 2009; 10 Suppl S2: 45-221.
16. Di Giambenedetto S, Bansi L, Sonnerborg A et al. Opposite trends in multiclass HIV-1 drug resistance and exhaustion of drug options in treatment-experienced patients undergoing resistance testing in 7 western European countries from 1997 to 2008. In: Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2010. Abstract 586. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
17. Hatano H, Hunt P, Weidler J et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis 2006; 43: 1329-36.
18. Cozzi-Lepri A, Phillips AN, Ruiz L et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007; 21: 721-32.
19. International AIDS Society/USA. http://www.iasusa.org/pub/topics/2009/issue5/138.pdf (5 January 2011, date last accessed).
20. Gotoh O. An improved algorithm for matching biological sequences. J Mol Biol 1982; 162: 705-8.
21. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
22. Prentice RL, Zhao LP. Estimating equations for parameters in means and covariances of multivariate discrete and continuous responses. Biometrics 1991; 47: 825-39.
23. Alcantara LCJ, Cassol S, Libin P et al. A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res 2009; 37: W634-42.
24. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2010. http://www.R-project.org (5 January 2011, date last accessed).
25. The PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 2011; 11: 273-83.
26. Taiwo B, Gallien S, Aga E et al. HIV-1 drug resistance evolution during persistent near target viral suppression. Antivir Ther 2010: 15 Suppl 2: A38.
27. Malet I, Delelis O, Soulie C et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 2009; 63: 795-804.
28. King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis 2005; 191: 2046-5.